MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$2,044K
EPS
-$0.05
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Income tax benefit
-0* --
License revenue
300 ---
General and administrative
2,072 -3,021* 1,889 11,179
Research and development
355 1,848* 2,551 1,953
In-process research and development impairment
-0* --
Total operating costs and expenses
2,427 -1,173 4,440 13,132
Gain from operations
-2,127 1,173* -4,440 -13,132
Foreign currency exchange (gain) loss
1 -26* 14 20
Interest income
82 109* 65 54
Total other income
83 83* 79 74
Net gain before income taxes
-2,044 1,255* -4,361 -13,058
Profit Loss
-1,255* --
Deemed Dividend From Warrant Inducement
-375* --
Net gain attributable to common stockholders
-2,044 880 -4,361 -13,058
Basic EPS
-0.05 0.044 -0.45 -1.93
Diluted EPS
-0.05 0.044 -0.45 -1.93
Basic Average Shares
41,072,725 19,992,617 9,676,521 6,752,953
Diluted Average Shares
41,072,725 19,992,617 9,676,521 6,752,953
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net gainattributable to common...-$2,044K Interest income$82K Foreign currencyexchange (gain) loss$1K Net gain beforeincome taxes-$2,044K Total other income$83K Gain from operations-$2,127K License revenue$300K Total operating costsand expenses$2,427K General andadministrative$2,072K Research and development$355K

Theriva Biologics, Inc. (TOVX)

Theriva Biologics, Inc. (TOVX)